Raymond James Financial Services Advisors, Inc. Lexicon Pharmaceuticals, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$66.3 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2020 Apr 21, 2020	SELL	$1.8 - $4.28 $25,831 - $61,422	-14,351 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$3.16 - $5.15 $45,349 - $73,907	14,351 New	14,351 $60,000

Others Institutions Holding LXRX

# of Institutions

122

Shares Held

159M

Call Options Held

2.11M

Put Options Held

412K

Artal Group S.A. Luxembourg, N4

118M
Shares

$195 Million
15.21% of portfolio
Black Rock Inc. New York, NY

7.69M
Shares

$12.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.4M
Shares

$10.6 Million
0.0% of portfolio
Orbimed Advisors LLC San Diego, CA

3.54M
Shares

$5.88 Million
0.19% of portfolio
Geode Capital Management, LLC Boston, MA

2.39M
Shares

$3.97 Million
0.0% of portfolio

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $313M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account